Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorec...(partner productcandidates may not issue ...),Health

Date:1/8/2008

partner product candidates may not issue, patents that have issued may not be enforceable or sufficient to protect against competitive products, or intellectual property licenses from third parties may be required in the future, (vi) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates, and (vii) potential competition from existing approved products (branded or generic) or product candidates under development by other companies could negatively impact the commercial potential of the company's product candidates due to such competitive factors as efficacy and safety profiles, pricing, and reimbursement by third party payers. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission (SEC), including its most recent Quarterly Report on Form 10-Q filed with the SEC on November 9, 2007. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. No information regarding or presented at the company's R&D day either posted on the company's website or presented orally or visually through the Webcast is intended to be incorporated by reference in this press release.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com

Stephan Herrera (415) 488-7699 or sherrera@nektar.com

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com

'/>"/>

SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
2. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
7. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma